These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 4668905)
1. Effect of phosphate binging agents on bone remodelling in patients on regular haemodialysis. Fournier A; Tunchot S; Bedrossian J; Sionest JG; Idatte JM; Bordier P Proc Eur Dial Transplant Assoc; 1972; 9():126-41. PubMed ID: 4668905 [No Abstract] [Full Text] [Related]
2. [Comparison of phosphate-binders in patients on regular hemodialysis (author's transl)]. Gahl G; Hopfenmüller W; Baethke R Med Klin; 1978 May; 73(19):710-4. PubMed ID: 651760 [No Abstract] [Full Text] [Related]
3. Total body calcium and long-term calcium balance in chronic renal disease. Denney JD; Sherrard DJ; Nelp WB; Chesnut CH; Baylink DJ J Lab Clin Med; 1973 Aug; 82(2):226-40. PubMed ID: 4721378 [No Abstract] [Full Text] [Related]
4. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599 [TBL] [Abstract][Full Text] [Related]
5. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis. Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465 [No Abstract] [Full Text] [Related]
6. Fluoride and dialysis osteodystrophy: results of a double-blind study. Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422 [No Abstract] [Full Text] [Related]
7. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354 [TBL] [Abstract][Full Text] [Related]
8. [Renal osteopathy and bone mineralisation in patients treated with dihydrotachysterol during long term dialysis (author's transl)]. Pogglitsch H; Schmidberger H; Gell G MMW Munch Med Wochenschr; 1976 Jan; 118(5):131-6. PubMed ID: 814443 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of intestinal phosphate binders in patients maintained by hemodialysis. Johnson WJ; O'Brien PC Nephron; 1978; 21(3):123-30. PubMed ID: 673095 [TBL] [Abstract][Full Text] [Related]
16. Bone and soft tissue changes with oral phosphate supplements. Laflamme GH; Jowsey J J Clin Invest; 1972 Nov; 51(11):2834-40. PubMed ID: 5080411 [TBL] [Abstract][Full Text] [Related]
17. [Uremic osteodystrophy. Critical evaluation of the radiologic and humoral indices of bone resorption]. Galmozzi C; Casati S; Rivolta E; De Vecchi A; Imbasciati E; Cecchettin M; Brancaccio D; Ponticelli C Minerva Nefrol; 1979; 26(3):405-8. PubMed ID: 262283 [No Abstract] [Full Text] [Related]
18. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients. Peacock M; Davison AM; Walker GS Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940 [No Abstract] [Full Text] [Related]
19. Effects of dialysate calcium and fluoride on bone disease during regular hemodialysis. Jowsey J; Johnson WJ; Taves DR; Kelly PJ J Lab Clin Med; 1972 Feb; 79(2):204-14. PubMed ID: 5009710 [No Abstract] [Full Text] [Related]
20. Bone disease in patients dialyzed with untreated water. Rashid A; Posen GA; Gray D; Jaworski ZF Med Instrum; 1974; 8(3):204-6. PubMed ID: 4838450 [No Abstract] [Full Text] [Related] [Next] [New Search]